TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11380230
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy (CRT) after radical resection
Study: 9222074
Drug: Alatrofloxacin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin 30 mg
Study: 9222074
Drug: Alatrofloxacin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin 100 mg
Study: 9222074
Drug: Alatrofloxacin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin 200 mg
Study: 9222074
Drug: Alatrofloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin 300 mg
Study: 9222074
Drug: Alatrofloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin (all doses)
Study: 8107184
Drug: Isosorbide-5-mononitrate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (60 mg)
Study: 3663551
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (150 mg) alone
Study: 3663551
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate in combination with human menopausal gonadotrophins (hMG)
Study: 3663551
Drug: Clomiphene in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene in combination with hMG
Study: 26695486
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg testosterone undecanoate (Nebido(®))
Study: 26695486
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate, and 100 mg testosterone decanoate (Sustanon(®))
Study: 21674594
Drug: Experimental OAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental OAB drug
Study: 11069725
Drug: Full irrigation
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full irrigation with 3000 ml of saline
Study: 11069725
Drug: Minimal irrigation
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal irrigation with 250 ml saline
Study: 9312318
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution 0.9%
Study: 8467542
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 2 ml bolus/10 min lockout interval
Study: 8467542
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 3 ml bolus/15 min lockout interval
Study: 8467542
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 4 ml bolus/20 min lockout interval
Study: 8467542
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 6 ml bolus/30 min lockout interval
Study: 8467542
Drug: Group E:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E: 8 ml/hr continuous infusion
Study: 3468737
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback treatment (8 sessions, twice a week for 4 weeks)
Study: 15854633
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral
Study: 10752774
Drug: Short-term glucose
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term glucose infusion of 25 g in 30 min
Study: 10752774
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose infusion of 10 g/h
Study: 8638536
Drug: Neoadjuvant intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant intraarterial infusion chemotherapy with 25 mg/m2 of cisplatin and 15 mg/m2 of bleomycin via each internal iliac artery.
Study: 8638536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving radiation therapy (external irradiation and intracavitary irradiation).
Study: 6533162
Drug: Intracarotid urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracarotid urokinase injections
Study: 22659373
Drug: Simvastatin alone
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin alone (40 mg/day)
Study: 22659373
Drug: Ezetimibe/Simvastatin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin combined therapy (10/20 or 10/40 mg/day)
Study: 20481650
Drug: Vicriviroc 75
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 75 mg alone
Study: 20481650
Drug: Vicriviroc 15
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 15 mg after 4 days of ritonavir 100 mg once daily
Study: 20481650
Drug: Ritonavir treatment
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir treatment
Study: 18588757
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation (daily until 6 months after RT)
Study: 12431355
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (Edmonston-Zagreb, Leningrad-Zagreb, RA 27/3 strains)
Study: 12431355
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (Moraten, Jeryl Lynn, Wistar 27/3 strains)
Study: 12431355
Drug: Vaccine C
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine C (Schwartz, Urabe AM-9, Wistar 27/3 strains)
Study: 10507269
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (0.25 mg, 0.50 mg, or 1.0 mg)
Study: 10507269
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (0.50 mg and 1.0 mg)
Study: 31918984
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval exercise (HIIE) with 10% evening basal insulin reduction
Study: 31918984
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval exercise (HIIE) with 20% evening basal insulin reduction
Study: 31918984
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval exercise (HIIE) with 30% evening basal insulin reduction
Study: 31358401
Drug: Red-blue irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red-blue irradiation treatment
Study: 25333776
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice daily for 26 weeks
Study: 23345636
Drug: Shoulder taping
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoulder taping and conventional treatment
Study: 23345636
Drug: Sham taping
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham taping and conventional treatment
Study: 12859140
Drug: Dalbavancin; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin; specific dosage and duration not mentioned.
Study: 11113028
Drug: Antipyretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyretic therapy (nonsteroidal anti-inflammatory drugs)
Study: 11113028
Drug: Antipyretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyretic therapy
Study: 1642652
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (AZA + MTX)
Study: 6430063
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 300 mg t.i.d.
Study: 27220523
Drug: Tablet PC
Normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC questionnaire
Study: 27220523
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods (tablet PC and paper)
Study: 22830517
Drug: LT peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT peel (lidocaine 70 mg/g and tetracaine 70 mg/g)
Study: 20586916
Drug: Endovascular therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapies (thrombolytic therapy)
Study: 12608943
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment at a dose of 10 mg/day for 12 months
Study: 10509846
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg on day 1, 200 mg daily on days 2‐4)
Study: 10509846
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg BID)
Study: 10509846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sparfloxacin and terfenadine
Study: 1940190
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid (AA, Supralox, 1 tablet three times a day 1 h a.c. and 2 tablets at bedtime, with acid binding capacity of 225 mEq)
Study: 1940190
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid (AA)
Study: 6757394
Drug: Work-site (WS)
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Work-site (WS) treatment program
Study: 29516455
Drug: Dolphin Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolphin Assisted Therapy (DAT)
Study: 27343343
Drug: Home-based upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based upper limb training program for 8 weeks, twice a week
Study: 18589766
Drug: Naoxinqing tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxinqing tablet
Study: 18589766
Drug: Naoxinqing tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxinqing tablet + half dose Simvastatin
Study: 18589766
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose Simvastatin
Study: 6666645
Drug: nomifensine 25-50
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nomifensine 25-50 mg taken three times daily
Study: 6666645
Drug: Motipress (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motipress (1.5 mg fluphenazine with 30 mg nortriptyline) taken once daily
Study: 27932449
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate 200 mg twice daily
Study: 19090898
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock six times a week
Study: 19090898
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock three times a week
Study: 16542788
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CT) with radiation therapy (RT)
Study: 16542788
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (CT) followed by radiation therapy (RT)
Study: 9101194
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C
Study: 3790403
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg biphasic release tablet of nifedipine
Study: 22437967
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level fluence 810 nm (15 Joules/cm(2)) laser diode therapy
Study: 15853819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with PTU (100 mg twice a day), propranolol (40 mg twice a day), and cholestyramine (4 g twice a day) for 4 weeks
Study: 15853819
Drug: PTU (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTU (100 mg twice a day) and propranolol (40 mg twice a day) for 4 weeks
Study: 10713872
Drug: N2O (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O (20, 40, 60, and 70% inhaled at 20-min intervals)
Study: 10713872
Drug: Ketamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.4 mg kg‐1 + 1.0 mg kg‐1h‐1)
Study: 2011259
Drug: Pramiracetam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam (up to 4,000 mg)
Study: 31251351
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) treatment at a dosage of 20 mg/kg before cardiac catheterization.
Study: 27886686
Drug: Preoperative warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative warfarin therapy
Study: 27886686
Drug: Postoperative warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative warfarin therapy
Study: 25488505
Drug: Treatment Control
Normalized name: SALICYLIC ACID 2 g in 100 mL TOPICAL LOTION [Lqd ACNE BLEMISH TREATMENT control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Control Condition (TCC)
Study: 17076695
Drug: S-3304 800
Normalized name: S-3304
DrugBank: S-3304 (DB12149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 800 mg
Study: 17076695
Drug: S-3304 1600
Normalized name: POLYQUATERNIUM-4 (1600 MPA.S AT 2%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 1600 mg
Study: 17076695
Drug: S-3304 2400
Normalized name: S-3304
DrugBank: S-3304 (DB12149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 2400 mg
Study: 17076695
Drug: S-3304 3200
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-3304 3200 mg
Study: 17076695
Drug: S-3304 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 (all doses)
Study: 9487416
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (glucose 25g i.v. with insulin 10 units i.v.)
Study: 9487416
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (50 mmol of 8.4% sodium bicarbonate infusion)
Study: 9487416
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (0.5mg of salbutamol i.v. in 50mls 5% dextrose)
Study: 9487416
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D (combination of treatments A and B)
Study: 9487416
Drug: Treatment E
Normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment E (combination of treatment B and C)
Study: 9487416
Drug: Treatment F
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment F (combination of treatments A and C)
Study: 9487416
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment G (combination of treatments A, B, and C)
Study: 8368735
Drug: VMCL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMCL plus low dose cyclophosphamide
Study: 8368735
Drug: VMCL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMCL treatment
Study: 3530861
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) tablets
Study: 21551317
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) propiverine 45 mg
Study: 21551317
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) propiverine 30 mg
Study: 21551317
Drug: Fat-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich meal before administration of propiverine
Study: 7630148
Drug: CNS 1102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNS 1102 (2 mg)
Study: 2774588
Drug: Cepharanthine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cepharanthine (50 mg intravenously every day during postoperative chemotherapy)
Study: 2774588
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no administration of Cepharanthine)
Study: 303115
Drug: Benoxaprofen 100
Normalized name: (±)-benoxaprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 100 mg
Study: 303115
Drug: Benoxaprofen 200
Normalized name: fenoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 200 mg
Study: 303115
Drug: Benoxaprofen 400
Normalized name: fenoprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 400 mg
Study: 303115
Drug: Benoxaprofen 25
Normalized name: (±)-benoxaprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 25 mg every 24 hours
Study: 303115
Drug: Benoxaprofen 50
Normalized name: (±)-benoxaprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 50 mg every 24 hours
Study: 303115
Drug: Benoxaprofen 100
Normalized name: (±)-benoxaprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 100 mg every 12 hours
Study: 303115
Drug: Benoxaprofen (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen (various doses)
Study: 31812127
Drug: Carbamazepine controlled-release
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine controlled-release (carbamazepine-CR)
Study: 24979880
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 80 mg/kg
Study: 11322638
Drug: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang) granules (7.5 g daily)
Study: 11322638
Drug: Kakkon‐to (Ge‐Gen‐Tang)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kakkon‐to (Ge‐Gen‐Tang) granules (7.5 g daily)
Study: 11322638
Drug: Sairei‐to (Cai‐Ling‐Tang)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sairei‐to (Cai‐Ling‐Tang) granules (9.0 g daily)
Study: 11322638
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no herbal medicine)
Study: 7524798
Drug: Piperacillin/tazobactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (3 g/375 mg every six hours)
Study: 7524798
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg every six hours) plus gentamicin (2.5 mg to 5.0 mg/kg every eight to 12 hours)
Study: 26860809
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (10g daily for 2 months)
Study: 24627419
Drug: Mipomersen 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 30 mg once daily
Study: 24627419
Drug: Mipomersen 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 70 mg 3 times weekly
Study: 30500603
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg once weekly
Study: 15746682
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost 1 mg up to 3 times daily for 2 days
Study: 15746682
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost
Study: 1307234
Drug: Vitamin supplement
Normalized name: Vitamin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplement (containing 12 vitamins including 0.8 mg of folic acid)
Study: 7970646
Drug: Trace-element supplement
Normalized name: chromic chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Study: 6364774
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU, d‐alpha‐tocopheryl acetate, by mouth twice daily for 20 weeks)
Study: 6364774
Drug: Placebo (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (by mouth twice daily for 20 weeks)
Study: 19827527
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with quinapril (23.3 ± 9.8 mg) and indapamide (1.5 mg)
Study: 16670131
Drug: Very-low-calorie diets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-calorie diets, pharmacotherapy, and lifestyle change
Study: 10325261
Drug: Trimegestone (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day) with continuous micronized oestradiol 2 mg daily for six treatment cycles
Study: 10325261
Drug: Trimegestone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone (various doses)
Study: 8609099
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release albuterol 8 mg, twice-daily (b.i.d.)
Study: 8609099
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release albuterol 8 mg, once daily at night
Study: 7064012
Drug: Furosemide 80
Normalized name: furosemide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 80 mg
Study: 7064012
Drug: Tizolemide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizolemide 100 mg
Study: 6388334
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (Tetracyclines)